Fellows will receive a competitive stipend and benefit package, including comprehensive health insurance.
Employer will assist with relocation costs.
Sunovion, in conjunction with MCPHS, offers a unique post-PharmD Fellowship program in Medical Affairs / Scientific Communications:
This two-year program is designed to provide talented candidates with a high-quality, comprehensive and unique postdoctoral experience. Candidates will gain practical industry experience at Sunovion. Candidates will also have opportunities to advance their academic skill set as an adjunct faculty member at MCPHS.
To be considered for an interview, please complete a fellowship application on the MCPHS SMApply application portal. Visit https://mcphs.smapply.io/
Please DO NOT request an interview within PPS. Our recruitment teams will contact qualified candidates via email to schedule interviews.
The MCPHS application portal will open up on October 3, 2022. Applicants must upload the following application materials to the online portal by November 11, 2022:
Letter of intent
Unofficial college transcript
Contact information for three references. References will receive an electronic recommendation form to complete separately.
Incomplete applications WILL NOT be reviewed. Interviews CANNOT be scheduled until these materials have been submitted. Please keep in mind that this is a competitive process and applicants are encouraged to complete their applications as soon as possible.
Three recommendation evaluation forms must be submitted no later than December 1, 2022, via the online portal. This is NOT a letter of recommendation but an online form that the reference will need to complete.
Rolling Application Review & Interviews
All submitted applications will be reviewed on a rolling basis. Interviews will also be offered on a rolling basis and opportunities are limited. Priority will be given to those applicants who apply early, well in advance of the deadline.
Rolling interviews will begin mid-October with pre-screens and a mixture of interview rounds, and will conclude in December at the end of the ASHP Midyear Clinical Meeting. Candidates will be notified if selected for an interview.
ASHP Midyear & Onsite Interviews
The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Las Vegas. Applicants are strongly encouraged to attend. Candidates attending in-person will not be able to interview without registering for both ASHP and PPS. Please refer to the ASHP & PPS website for registration details.
Top candidates may be invited for interviews at the sponsoring company’s location pending COVID – 19 restrictions.
Recognizing that the choice of a Post-Doctoral Industry Fellowship is an important decision, MCPHS in conjunction with the Academic Industry Fellowship Alliance (AIFA), has agreed to extend offers for Fellowships no earlier than December 7, 2022.
Final candidates will be required to go through additional screening / onboarding as required by MCPHS.
The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis. Applicants must have a Doctor of Pharmacy degree from an ACPE accredited college of pharmacy at the commencement of the program.
Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
All candidates must have authorization to work in the United States throughout the duration of the one or two year fellowship. No visa sponsorship will be provided (i.e., TN, H-1B, STEM OPT, etc.).
Sunovion is a leading pharmaceutical company dedicated to discovering, developing, and commercializing therapeutic products that advance the science of medicine in the areas of psychiatry, neurology, and respiratory disease to improve the lives of patients and their families.
Sunovion brings together scientific focus, pragmatism, and dedication to research with an entrepreneurial energy and willingness to take on any challenge, always keeping the longer view in sight. We’ll continue to develop therapies in two distinct treatment areas—central nervous system disorders and respiratory ailments—as well as explore other therapeutic areas. We will continue to work with national and international partners to keep a constant stream of new drugs flowing into the pipeline. Because we at Sunovion put our patients front and center, we work every day to fulfill the promise of “Innovation Today, Healthier Tomorrows”.